Medrad + Possis
Muralidhar R
New Cardiovascular Products Division Launches at TCT2008
The merger between MEDRAD and Possis(R) Medical Inc. has resulted in a new MEDRAD cardiovascular division focused on advancing interventional medicine
-- The new name and branding for MEDRAD, INC.'s new interventional products division was unveiled to the public today at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, Oct. 12 -- 17th in Washington D.C. Operating under the new name MEDRAD Interventional(TM)/Possis(R), the division combines a number of market-leading products such as the AngioJet(R) Thrombectomy System, the MEDRAD Avanta(R) Fluid Management Injector System, Mark V ProVis(R) Angiographic Injection System, and Fetch(R) Aspiration Catheter, among others.
"We are very excited about the synergies created in this new division," said John Friel, president and CEO of MEDRAD. "Possis Medical and our former cardiovascular business unit complement each other extremely well, and the resulting team is experienced and well positioned to serve the needs of interventional cardiology, interventional radiology and vascular surgery. The name and brand tells the purpose and shows the heritage of our new division," said Friel.
MEDRAD Interventional/Possis chose to launch its new brand at TCT2008 because of the importance of the conference to interventional physicians. "The attendees at the TCT conference represent our key customers," according to Bob Dutcher, president of MEDRAD Interventional/Possis.
"The doctors and medical specialists we serve are likely to attend or closely follow the activities of the TCT conference, so introducing our new name and look there seemed most appropriate," said Dutcher.
The new interventional division of MEDRAD increases the international reach of the former Possis Medical product portfolio with sales operations in over 30 countries. Possis brings its interventional sales team to the new division, which significantly expands the market presence for the MEDRAD interventional products in the U.S. Both groups have extensive research and development capabilities which will continue to focus on improved technology and innovation for interventional medicine.
About MEDRAD Interventional/Possis
Possis Medical, a pioneer in the field of thrombus removal, has recently merged with MEDRAD, the leader in diagnostic and interventional contrast injection. Together, they have formed MEDRAD Interventional/Possis, a division of MEDRAD, INC., focused on advancing interventional medicine through research, innovation, and customer care. With manufacturing facilities in both Minneapolis, MN and Pittsburgh, PA, MEDRAD Interventional/Possis manufactures and markets segment-leading medical devices such as AngioJet Thrombectomy Systems, MEDRAD Avanta Fluid Management Injector Systems, Mark V ProVis Angiographic Contrast Injectors, FETCH Aspiration Catheters and the SafeSeal (R) Hemostasis Patch.
MEDRAD, INC. is an affiliate of Bayer AG. More company information is available at www.medrad.com. The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Thanks & regards,
Muralidhar Rejeti.
---